Replies to post #130255 on Anavex Life Sciences Corp (AVXL)

[Amatuer17]

Do you think the new set of rules will make that much difference?

Anyway - what about Rett and PD? Why they are not started?

[OFP]

if Anavex simply maintains the status quo of the single current 25 patient trial that Australia is subsidizing.

Is Australia subsidizing?

Beyond tax credits available to any biotech company that sets up shop there? If not, maybe the expectations (from others) that Australia is going to have a role going forward should be tempered.

[Rubyred77]

Missling himself said around 300 patients so that point is moot debating.

Revamping the FDA guidelines helps speed up the process of getting access of said drug to patient, as long as it is safe. So again, 2-3 years is a bit far fetched. Especially with 25 patients already in the 2-3 year realm and still providing useful data. So the p2a/b continuing data along with the p2/3 at even 1 year would get the longs here across the finish line.

With Axon, NTRP, BIIB and every other BP failing to provide a better than soc treatment for Alz, it's taking the little pharmas to lead the charge and discover new possibilities only to then get bought out by BP. Now, do you REALLY think BIIB didn't try and buy Anavex on the cheap?